CinnaGen Reports Study Results of Biosimilar Teriparatide for the Treatment of Osteoporosis
Shots:
- The study evaluating biosimilar teriparatide (20μg, qd) in 239 patients, showed an improvement in bone mineral density (BMD) in patients with osteoporosis treated for a year or more according to Bone Reports, patients received biosimilar teriparatide for 12-16/17-20/21-24mos. were 27.62%/14.64%/57.74%, respectively
- T-score (SD) at lumbar spine & femoral neck increased from –2.67 to –2.26 & 2.18 to –2.09; patients with maintained or improved BMD T-score at both sites were 85.36% & 69.04%. Similar results were obtained in subgroups of patients with RA & those with a history of a previous fracture or parental hip fracture
- Biosimilar teriparatide can be considered an effective treatment option in female and male patients with osteoporosis
Ref: CinnaGen | Image: CinnaGen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
